Adults 30 to 110, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Area Under the Curve for Cancer Detection Rates of CESM Compared With Breast MRI for Breast Cancer ScreeningPrimary· 2 years
We will determine whether CESM is non-inferior to breast MRI for breast cancer detection by comparing cancer detection rates on both studies using a multi-case multi-reader study model.
Group
Value
95% CI
Cancers Identified With CESM
0.91
.885 – 0.926
Cancers Identified With Screening MRI
.91
0.894 – 0.925
Area Under the Curve for Cancer Detection Rates of CESM Compared With Abbreviated Breast MRI for Breast Cancer ScreeningSecondary· 2 years
Radiologist readers evaluated CEM and abbreviated MRI in 132 patients, some who had cancer and some who did not. The area under the curve was determine for each reader for each exam type.
Group
Value
95% CI
CESM
.906
.885 – 0.926
Screening Abbreviated MRI
.894
.859 – .929
Area Under the Curve for Cancer Detection Rates of CESM Compared With Conventional 2d Mammography for Breast Cancer ScreeningSecondary· 2 years
We will determine whether CESM is superior to conventional 2D mammographic screening using a multi-case multi-reader study model.
Group
Value
95% CI
CESM
.906
.885 – .926
Screening 2D Mammography
.788
.756 – .820
Sponsor's own description
This research study is evaluating whether contrast enhanced mammography can be used as an alternative to breast Magnetic Resonance Imaging (MRI) for cancer screening
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06148038 — CBD for Breast Cancer Primary Tumors
· Phase 1
· recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R
· Phase 2
· recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
· Phase 2
· recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer
· NA
· recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
· Phase 2
· recruiting
Other Beth Israel Deaconess Medical Center trials
Trials by the same sponsor.
NCT07352657 — Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices: The RAPTOR-CIED Study (Main Phase)
· NA
· not yet recruiting
NCT07531602 — Effect of PEEP on Cardiac Function
· NA
· not yet recruiting
NCT07534683 — Primed to Thrive: Investigating the Combined Impact of Mindfulness Education and Meditation Practice on Psychological an
· NA
· not yet recruiting
NCT07277244 — Low-Intensity Mechanical Ventilation in the Operating Room: a Pilot Study
· NA
· enrolling by invitation
NCT06896474 — SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beth Israel Deaconess Medical Center
Last refreshed: 9 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03482557.